Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.

Disclosure: The author does not hold a position in NTLA.

← Back to Free Index

NTLA

Analysis as of: 2026-04-21

Intellia Therapeutics, Inc.

Clinical-stage biotechnology company developing in vivo CRISPR gene-editing therapies for hereditary angioedema, transthyretin amyloidosis, and other severe diseases.

biotech healthcare

On Yahoo Finance ...

Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Pivotal HAE Data Could Create a Franchise

The next five years hinge on turning one late-stage CRISPR asset into a commercial rare-disease engine. If that happens, product revenue can fund the platform; if not, valuation likely falls back toward binary pipeline optionality.

Analysis

Thesis

If HAELO supports approval and lonvo-z launches in 2027, Intellia can move from a binary platform story to a real rare-disease franchise, with HAE funding the company, ATTR rebuilding optionality, and smarter partnering monetizing platform learning without needing full platform perfection by 2031.

Last Economy Alignment

AI helps discovery, trial ops and safety surveillance, but Intellia is still gated by biology, regulation and manufacturing rather than software-like scale.

Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple

4.5x (from 5 most recent analyses)

Reasoning

The upside comes from a category change. A positive HAE readout and timely filing would make Intellia look less like a speculative gene-editing platform and more like a commercial rare-disease company with follow-on platform value. That re-rating can be meaningful even if ATTR only gets partial credit by 2031 and even if investors stay somewhat skeptical after the prior hold history.

Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary

This is a milestone-fragile story. The optimistic case is driven by one pivotal HAE readout turning Intellia into a commercial rare-disease company, while the main failure modes are regulatory trust, slower-than-expected one-time-therapy adoption, and dilution if timelines slip. ATTR is valuable upside, but it is still rebuilding credibility after the liver-safety hold.

Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Trends

Key Changes

No material clinical, regulatory, or financing update was posted in the last 7-10 days; the setup still points to mid-2026 HAELO topline as the binding event.
The latest operating posture remains unchanged: planned lonvo-z BLA in 2H26, launch goal in 1H27, and continued restart work across the nex-z Phase 3 program.
Recent filings were governance or equity-administration housekeeping rather than thesis-changing pipeline signals.

Forecast update

The framework is slightly more tempered because a one-time HAE therapy likely monetizes backlog early and then normalizes, while ATTR still deserves a post-hold timing discount.

Upgrade to Builder to also access: Future Considerations

Last Economy Structure

AI Industrial Score

0.27

They control real gene-editing know-how, human safety data and a late-stage rare-disease launch path, so AI can help them design, monitor and commercialize faster. But the thing that matters most is still clinical proof and regulator trust, and if safety wobbles again software gains will not save the story.

Upgrade to Reader to also access: Score Decomposition, Confidence Level

Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility

Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target

$20.45

Upgrade to Reader to also access: Bull Case, Base Case, Bear Case

Next Arc Research